Lenalidomide来那度胺（雷利度胺）

[Functions and Indications of Ranaridamide]
1. Multiple myeloma, which can be used to treat chronic myeloma that has received at least one therapy.
2. Myelodysplastic Syndrome, Indian rellidomide is used to treat severe anemia caused by Myelodysplastic Syndrome with 5q chromosome deletion.

“Model and specification”
Capsule: 5mg/ capsule; 10mg/ capsule; 15mg/ capsule; 25mg/ capsule

【 Usage and dosage 】
Lenalidomide is an oral capsule, which is produced in four specifications: 5mg, 10mg, 15 mg and 25 mg. Myelodysplastic syndrome should take 10mg of Indian lenalidomide every day. Multiple myeloma takes 25mg every day. Take it in warm water, and drink a large glass of warm water when taking the medicine. The dosage of Indian leradotamide can be adjusted according to the changes of patients’ clinical symptoms and laboratory results.

[Clinical research]
The US Food and Drug Administration (fda) approved lenalidomide/revlimid from American Cytogenetics Company. Revlimid is an oral preparation, and evlimid(lenalidomide) is a drug developed by celgene Company for the treatment of fatal blood diseases and cancer. This product is an enhanced version of thalidomide, which has been used to treat thousands of birth defects caused by morning sickness, and has anticancer potential. Compared with thalidomide, it has fewer adverse reactions, and studies have proved that it will not cause birth defects in infants.
In September, 2005, fda Cancer Drug Advisory Committee recommended revlimid for the treatment of infusion-dependent anemia. In October, the European Medicines Agency accepted revlimid’s listing application.
Celgene plans to submit the application of this product for the treatment of relapsed and refractory multiple myeloma to the US fda and the European Drug Administration respectively in the first quarter of 2006.
Revlimid has effects on many biological pathways in cells. Celgene Company is still evaluating the hematological and oncological therapeutic effects of this product, including multiple myeloma, myelodysplastic syndrome, chronic lymphocytic leukemia and solid tumor. Myelodysplastic syndrome (MDS) is a malignant blood disease with about 300,000 patients worldwide. Myelodysplastic syndrome occurs when blood cells in bone marrow are always in an immature stage and cannot perform their necessary functions. Bone marrow is full of these immature cells, which inhibits the development of normal cells. Patients with myelodysplastic syndrome must always rely on blood transfusion to resist anemia, fatigue and other symptoms until they develop into life-threatening iron overload or iron poisoning. The treatment of this disease urgently needs a radical method, not just controlling the symptoms. More than half of patients with myelodysplastic syndrome have been diagnosed with cytochromosomal variation, including partial or complete deletion of more than one chromosome. The most common chromosomal abnormality in myelodysplastic syndrome is the Q deletion of chromosomes 5, 7 and 20. Another common variation is the extra copy of chromosome 8. The proportion of 5q chromosome deletion in patients with myelodysplastic syndrome can reach 20% ~ 30%.
Revlimid is an oral preparation with low toxicity, which will become one of the treatment options for patients with myelodysplastic syndrome.

【 Precautions 】
Doctors should provide medication guidance to patients every time they prescribe loratadine, and doctors or pharmacists should take this opportunity to explain the possible risks of loratadine to patients. It is best for patients who are ready to take medicine to take two different effective contraceptive measures at the same time. Female patients who are going to take Liladomide should sign an informed consent form under the guidance of a doctor to show that they already know the importance of contraception when taking Liladomide. In addition, all female patients with pregnancy possibility need to undergo two pregnancy tests before taking the drug (one is arranged 10-14 days before taking the drug, and the other is arranged within 24 hours before taking the drug), and only those who have negative results from the two pregnancy tests can formally take lerodomide.

[Adverse reactions and contraindications]
The most common adverse reactions of loratadine were thrombocytopenia (61.5%) and neutropenia (58.8%). Other common adverse reactions include diarrhea, itching, rash, fatigue, constipation, nausea, nasopharyngitis, joint pain, fever, back pain, peripheral edema, cough, dizziness, headache, muscle cramps, dyspnea and pharyngitis.

[taboo]
It is forbidden for women with allergic history, pregnancy and lactation, and it is not suitable for those who have undergone chemotherapy and radiotherapy in the near future and have leukopenia.

[Drug for children]
There is no clinical study on the safety and effectiveness of this product for children.

[storage]
It should be kept below 30 C. The validity period is 2 years, and the production date is at the top of the box.

[Manufacturer]
NATCO PHARMA, India